Literature DB >> 10695779

Phamacokinetics of a single oral dose of dihydroartemisinin in Vietnamese healthy volunteers.

N H Le1, K Na-Bangchang, T D Le, K A Thrinh, J Karbwang.   

Abstract

Pharmacokinetics of a 240 mg single dose of oral dihydroartemisinin (DHA) was investigated in 8 healthy (5 males, 3 females) Vietnamese volunteers. Plasma concentrations were measured by high-performance liquid chromatography with electrochemical detection in the reductive mode. The concentration time profile of DHA was fitted with one-compartment model with a lag time. Pharmacokinetics of DHA is comparable between males and females even when adjusted with dosage. The median (range) values of pooled pharmacokinetics of oral DHA were: t(lag) 0.41 (0.09-0.78) hours, t(1/2z) 0.58 (0.17-1.43) hours, t(max) 1.6 (1.1-2.2) hours, Cmax 466 (128-787) ng/ml. Cmax/dosage 97.7 (27.2-124.6) ng/ml, t(1/2z) 2.0 (1.5-3.4) hours, AUC 1867 (420-3535) ng x h/ml, AUC/dosage 364.3 (89.3-559.7) ng x h/ml/dosage, Cl/f 45.8 (30.0-190.0) ml/min/kg, Vz/f 8.0 (5.5-29.9) l/kg. Interindividual variation was large, the coefficients of variation (CV) were 47.8% and 45.3% respectively to AUC and Cmax. The t(max) of DHA formulation was comparable with that of DHA metabolite of artemisinin derivatives. The t(1/2z) was longer and shorter than that of DHA metabolites of oral formulations of artesunate and artemether, respectively. For monotherapeutic regimen(s) of DHA, dosing frequency of at least twice a day is suggested. Combined regimen(s) of DHA with other potent, long half-life antimalarials may also be an alternative approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695779

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  7 in total

1.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.

Authors:  Joel Tarning; Marcus J Rijken; Rose McGready; Aung Pyae Phyo; Warunee Hanpithakpong; Nicholas P J Day; Nicholas J White; François Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

4.  Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.

Authors:  Nguyen Trong Chinh; Nguyen Ngoc Quang; Nguyen Xuan Thanh; Bui Dai; Jason P Geue; Russell S Addison; Thomas Travers; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

5.  Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.

Authors:  James S McCarthy; Mark Baker; Peter O'Rourke; Louise Marquart; Paul Griffin; Rob Hooft van Huijsduijnen; Jörg J Möhrle
Journal:  J Antimicrob Chemother       Date:  2016-06-05       Impact factor: 5.790

6.  Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.

Authors:  Palang Chotsiri; Thanaporn Wattanakul; Richard M Hoglund; Borimas Hanboonkunupakarn; Sasithon Pukrittayakamee; Daniel Blessborn; Podjanee Jittamala; Nicholas J White; Nicholas P J Day; Joel Tarning
Journal:  Br J Clin Pharmacol       Date:  2017-08-16       Impact factor: 4.335

7.  Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis.

Authors:  Jie Jiang; Guojun Geng; Xiuyi Yu; Hongming Liu; Jing Gao; Hanxiang An; Chengfu Cai; Ning Li; Dongyan Shen; Xiaoqiang Wu; Lisheng Zheng; Yanjun Mi; Shuyu Yang
Journal:  Oncotarget       Date:  2016-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.